Dr. Reddy's Launches First-to-Market Generic Bosutinib 400mg in the U.S., Challenging Pfizer's Bosulif
Key Insights
Dr. Reddy's Laboratories announced the first-to-market launch of generic Bosutinib Tablets 400mg in the United States on June 13, 2026.
The product is a generic equivalent of Pfizer subsidiary Wyeth's Bosulif and was a first-to-file product eligible for 180 days of generic drug exclusivity.
The Bosulif brand (400mg) had U.S. sales of approximately $253.8 million for the 12-month period ended April 2026, per IQVIA data.
Dr. Reddy's Laboratories announced on June 13, 2026, the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Pfizer subsidiary Wyeth's cancer drug Bosulif, in the United States. The launch marks a significant expansion of the company's oncology portfolio and introduces a lower-cost alternative for patients with Philadelphia chromosome-positive chronic myelogenous leukemia (search) (Ph+ CML).
The product was a first-to-file submission, making it eligible for 180 days of generic drug exclusivity for the 400mg strength in the U.S. market. This exclusivity period grants Dr. Reddy's a temporary monopoly on the generic version, allowing the company to establish market presence before additional generic competitors can enter.
Collaboration with MSN Laboratories (search)
Dr. Reddy's developed the product in collaboration with Hyderabad-based MSN Laboratories (search) Private Limited. Under the terms of the partnership, Dr. Reddy's holds the exclusive marketing rights for Bosutinib Tablets in the United States, while MSN is responsible for the development and manufacturing of the product.
"The successful development and commercialization of Bosutinib Tablets demonstrates MSN's strong scientific, regulatory, and manufacturing capabilities in complex oncology products," said Bharat Reddy, Executive Director of MSN Laboratories (search). "We remain committed to delivering high-quality, affordable medicines globally through efficient development and reliable manufacturing excellence."
Market Significance
The Bosulif brand (400mg) generated U.S. sales of approximately $253.8 million for the latest 12-month period ended April 2026, according to IQVIA National Sales Perspectives data. The availability of a generic alternative is expected to reduce costs for patients and healthcare systems.
Milan Kalawadia, CEO-North America of Dr. Reddy's Laboratories, emphasized the strategic importance of the launch: "This launch highlights our commitment to leading with timely market entry for high-priority therapies while broadening access for both patients and healthcare providers. With this launch, we remain focused on strengthening our oncology portfolio and partnering across the healthcare system to ensure that critical treatments are both accessible and affordable."
Clinical Indication
According to the U.S. FDA, Bosulif (bosutinib) is a kinase inhibitor indicated for the treatment of adult patients with newly-diagnosed chronic phase Ph+ CML, as well as chronic, accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy. The drug targets the BCR-ABL (search) kinase, a key driver of CML pathogenesis.
Dr. Reddy's, headquartered in Hyderabad, India, and with North American operations based in Princeton, New Jersey, continues to build its presence in the U.S. generic oncology market through strategic first-to-file opportunities and partnerships.